Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Renalytix ( (GB:RENX) ) has issued an update.
Renalytix has announced revised revenue guidance, projecting significant growth due to its collaboration with Tempus AI, Inc. The company expects revenues to reach $8.4 million in FY26, $19 million in FY27, and $42 million in FY28, reflecting the positive impact of the partnership. This collaboration is anticipated to enhance Renalytix’s market positioning and operational capabilities as it integrates its technology into hospital systems and healthcare providers.
Spark’s Take on GB:RENX Stock
According to Spark, TipRanks’ AI Analyst, GB:RENX is a Underperform.
Renalytix’s overall stock score is low due to severe financial challenges, including declining revenues, high operating losses, and solvency issues. Despite positive corporate events suggesting strategic interest and growth potential, the technical analysis and valuation remain weak, impacting the stock’s appeal.
To see Spark’s full report on GB:RENX stock, click here.
More about Renalytix
Renalytix is an artificial intelligence-enabled in vitro diagnostics company focused on optimizing clinical management of kidney disease to improve patient outcomes. The company offers kidneyintelX.dkd, the only FDA-approved and Medicare reimbursed prognostic test for early-stage risk assessment in chronic kidney disease, which is commercially available in the United States.
Average Trading Volume: 2,168,426
Technical Sentiment Signal: Hold
Current Market Cap: £35.6M
See more data about RENX stock on TipRanks’ Stock Analysis page.